Industry Briefs: Apr. 23, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: Apr. 23, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

3M Drug Delivery Systems has expanded its pressurized metered dose inhaler fill line at its facility in Northridge, California. Read More

Baxter International will invest $1 billion over the next five years for a new manufacturing facility in Georgia for plasma-derived therapies. Read More

Eisai has amended its license agreement with Teikoku Pharma USA for the Aricept transdermal patch system. Read More

Kemwell Biopharma has expanded its pharmaceutical development laboratories, including a 7500-ft2 cGMP pilot facility, in Bangalore, India, to support pharmaceutical projects from preformulation to finished products.

Merck Millipore, the life-science division of Merck KGaA, has announced the schedule for the Merck Millipore Live Lab Tour 2012 that will visit nine science parks and institutions in Europe during May–June 2012. Click here for the schedule and more details.

Mylan is expanding its operations in Dublin and Galway, Ireland. Read More

Patheon has formed Patheon Certified Consultants, a new consulting services comprised of industry professionals to assist emerging biotechnology and pharmaceutical companies. Read More

West Pharmaceutical Services has dedicated new cleanroom manufacturing capabilities at its Scottsdale, Arizona, pharmaceutical delivery systems engineering center. West will manufacture its Daikyo Crystal Zenith 1-mL long prefillable syringe system at the Scottsdale facility.

People News

AMRI has appointed Christopher Conway and Louis Garguilo as vice-president in its business-development units. Read More

Novasep has appointed Jean-Claude Romain as corporate quality director and Alain Lamproye as director of the company’s bioproduction sites in Belgium. Read More

Quintiles has named Tom Pike as CEO. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here